EUVIMEDSkopri EUVIMED
Vergleichsstudie

Evaluation of Single Versus Two‐Dose Basiliximab Induction Therapy in Live‐Donor Liver Transplant

Benjamin N Herrmann iD, Cody A Moore, Heather J Johnson, Abhinav Humar, Kristen A Shimko

Clinical Transplantation · 2024

DOI: 10.1111/ctr.70006 ↗

At a glance

Vergleichsstudie in Clinical Transplantation, 2024. Written by Benjamin N Herrmann and 4 co-authors. Institution: Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Major MEDLINE topics: Basiliximab, Liver Transplantation, Recombinant Fusion Proteins, Graft Rejection. Cited 3 times so far (Crossref); 26 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Basiliximab is a high‐cost induction agent typically given as two doses in liver transplant recipients. This study evaluated renal outcomes in live‐donor liver transplant recipients (LDLTRs) with stable renal function at the time of transplant receiving one versus two doses of basiliximab.

Methods

We retrospectively identified 231 adult LDLTR with a serum creatinine (SCr)

Subjects

MeSH terms (MEDLINE)

BasiliximabLiver TransplantationRecombinant Fusion ProteinsGraft RejectionImmunosuppressive AgentsAntibodies, MonoclonalLiving DonorsHumansMaleFemaleRetrospective StudiesMiddle AgedFollow-Up StudiesGraft SurvivalAdultPrognosisAcute Kidney InjuryPostoperative ComplicationsRisk FactorsKidney Function TestsInduction ChemotherapyGlomerular Filtration Rate

Author keywords

acute cellular rejectionacute kidney injurybasiliximabinduction immunosuppressionliver transplantlive‐donor liver transplantpharmacoeconomics

Substances

BasiliximabRecombinant Fusion ProteinsImmunosuppressive AgentsAntibodies, Monoclonal

Authors and institutions

  • Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
  • Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

ORCID profiles: Benjamin N Herrmann

Cite

APA

Herrmann, B. N., Moore, C. A., Johnson, H. J., Humar, A., & Shimko, K. A. (2024). Evaluation of Single Versus Two‐Dose Basiliximab Induction Therapy in Live‐Donor Liver Transplant. Clinical Transplantation. https://doi.org/10.1111/ctr.70006

Vancouver

Herrmann BN, Moore CA, Johnson HJ, Humar A, Shimko KA. Evaluation of Single Versus Two‐Dose Basiliximab Induction Therapy in Live‐Donor Liver Transplant. Clinical Transplantation. 2024. doi:10.1111/ctr.70006

BibTeX
@article{Herrmann2024,
  author = {Herrmann, Benjamin N and Moore, Cody A and Johnson, Heather J and Humar, Abhinav and Shimko, Kristen A},
  title = {Evaluation of Single Versus Two‐Dose Basiliximab Induction Therapy in Live‐Donor Liver Transplant},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.70006}
}
Start for free →